Fortress Biotech, Inc. (FBIO) EPS Estimated At $-0.57

February 23, 2018 - By Michael Pereira

 Fortress Biotech, Inc. (FBIO) EPS Estimated At $ 0.57

Analysts expect Fortress Biotech, Inc. (NASDAQ:FBIO) to report $-0.57 EPS on March, 15.They anticipate $0.14 EPS change or 32.56 % from last quarter’s $-0.43 EPS. After having $-0.67 EPS previously, Fortress Biotech, Inc.’s analysts see -14.93 % EPS growth. The stock increased 4.96% or $0.18 during the last trading session, reaching $3.81. About 209,577 shares traded or 69.59% up from the average. Fortress Biotech, Inc. (NASDAQ:FBIO) has risen 52.16% since February 23, 2017 and is uptrending. It has outperformed by 35.46% the S&P500.

Fortress Biotech, Inc. (NASDAQ:FBIO) Ratings Coverage

Among 2 analysts covering Fortress Biotech (NASDAQ:FBIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fortress Biotech had 7 analyst reports since July 11, 2017 according to SRatingsIntel. H.C. Wainwright maintained the shares of FBIO in report on Tuesday, December 12 with “Buy” rating. The company was maintained on Tuesday, July 11 by H.C. Wainwright. H.C. Wainwright maintained the shares of FBIO in report on Wednesday, September 27 with “Buy” rating. The firm earned “Buy” rating on Thursday, August 10 by H.C. Wainwright. H.C. Wainwright maintained Fortress Biotech, Inc. (NASDAQ:FBIO) on Tuesday, December 5 with “Buy” rating. The firm earned “Buy” rating on Tuesday, January 2 by H.C. Wainwright.

Fortress Biotech, Inc., a biopharmaceutical company, engages in dermatology product sales, pharmaceutical, and biotechnology businesses in the United States. The company has market cap of $193.00 million. The firm offers CNDO-109, a lysate that activates donor natural killer cells to treat cancer-related and other conditions; tramadol HCl, an intravenous formulation for moderate to moderately severe post-operative pain; CAEL-101 for AL amyloidosis; and CEVA101, which is in Phase II clinical study for severe traumatic brain injury in pediatric patients and adults. It currently has negative earnings. It also provides novel, non-chemotherapy, and immune-enhanced combination treatments for patients with solid tumor cancers; Uracil Topical Cream that is in Phase II to treat and prevent hand-foot syndrome; candidate CUTX-101, a copper histidinate injection for Menkes disease and related copper transport disorders; and novel agents for rare, neglected, or orphan disorders.

More notable recent Fortress Biotech, Inc. (NASDAQ:FBIO) news were published by: Globenewswire.com which released: “Fortress Biotech Announces Cellvation’s CEVA101 Granted FDA Regenerative …” on November 08, 2017, also Globenewswire.com with their article: “Fortress Biotech Announces Pricing of Series A Preferred Stock Offering” published on November 07, 2017, Globenewswire.com published: “Fortress Biotech Announces Positive Clinical Data From Fortress Companies …” on December 11, 2017. More interesting news about Fortress Biotech, Inc. (NASDAQ:FBIO) were released by: Globenewswire.com and their article: “Fortress Biotech Forms Subsidiary Tamid Bio to Develop Novel AAV Gene …” published on December 05, 2017 as well as Globenewswire.com‘s news article titled: “Fortress Biotech Announces Proposed Public Offering of Series A Preferred Stock” with publication date: November 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: